Tyler Basen, MD
Allergy & Immunology · Mission Viejo, CANPI 1184069692
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $112,963 of the $150,366 with a category attached, or 75.1%. GSK accounts for 91.0% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2023 at $100,930 and has fallen 97.3% since, to $2,751 in 2025. Among allergy & immunology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 607 payments — averaging $247.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$137K
- Sanofi$4K
- Regeneron Healthcare Solutions, Inc.$3K
- AstraZeneca$1K
- Takeda Pharmaceuticals U.S.A., Inc.$936
- Incyte Corporation$813
- plus $4K from 27 others
What the payments were for
- Consulting fees$3,7753%
- Speaking & faculty fees$112,96375%
- Travel & lodging$19,34113%
- Food & beverage$14,28810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 199 | $136,809 |
| Sanofi | 75 | $3,579 |
| Regeneron Healthcare Solutions, Inc. | 22 | $2,520 |
| AstraZeneca | 60 | $1,218 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $936 |
| Incyte Corporation | 51 | $813 |
| Pfizer | 28 | $660 |
| Novartis | 29 | $610 |
| LEO Pharma Inc. | 13 | $447 |
| Octapharma USA, Inc. | 5 | $406 |
| Genentech USA, Inc. | 13 | $314 |
| CSL Behring | 10 | $237 |
| Boehringer Ingelheim | 10 | $179 |
| Optinose US, Inc. | 8 | $167 |
| Alk-abello, Inc | 7 | $161 |
| Amgen(2 entities) | 6 | $156 |
| NEW World Medical,inc. | 1 | $147 |
| AbbVie(2 entities) | 3 | $136 |
| Intuitive Surgical | 1 | $126 |
| Kaleo, Inc. | 5 | $121 |
| Biocryst US Sales Co., LLC | 4 | $121 |
| Galderma Laboratories, L.p. | 5 | $113 |
| Philips North America LLC | 5 | $93 |
| Grifols USA, LLC | 3 | $56 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Ionis Pharmaceuticals, Inc. | 1 | $36 |
| Lilly USA, LLC | 1 | $30 |
| Cycle Pharmaceuticals Inc | 1 | $28 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $27 |
| Jubilant Hollisterstier LLC | 1 | $24 |
| Arcutis Biotherapeutics, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $19 |
| Organon | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$108,070
- DUPIXENT$3,725
- TRELEGY ELLIPTA$3,700
- CUTAQUIG$259
- Kahook Dual Blade$147
- Clearpath$147
- Ahmed Glaucoma Valve$147
- Streamline$147
- Via360$147
- Da Vinci Surgical System$126
- NUCALA$125
- OPZELURA$114
How this compares
$150,366 in reported general payments places this provider in the 95th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 28 | $117,466 |
| Dupixent PenDupilumab | 15 | $102,783 |
| XolairOmalizumab | 38 | $102,594 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $41,698 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $27,530 |
| Advair HfaFluticasone Propion/Salmeterol | 36 | $11,969 |
| Ipratropium Bromide | 87 | $2,465 |
| Epinephrine | 12 | $2,030 |
| Tacrolimus | 13 | $1,772 |
| Azelastine Hcl | 73 | $1,352 |
| Wixela InhubFluticasone Propion/Salmeterol | 20 | $1,130 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 59 | $980 |
| Montelukast Sodium | 98 | $540 |
| Famotidine | 15 | $185 |
| Fluticasone Propionate | 24 | $164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $936 | $117,46628 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $136,809 | $69,227123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in Mission Viejo
- Raffi TachdjianSanta Monica$3.7M
- Bob GengSan Diego$3.3M
- Vinay MehtaLaguna Niguel$1.3M
- Andrew WhiteSan Diego$752K
- Marc RiedlSan Diego$725K
- Katharine WoessnerSan Diego$581K
- Brian Modenala Jolla$453K
- Heena Shah PatelUpland$428K
- Jacob OffenbergerGranada Hills$419K
- Myron LiebhaberSanta Barbara$354K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.